The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
COVID-19, Arrhythmic Risk, and Inflammation: Mind the Gap!
Abstract
oronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). 1Besides direct tissue invasion, SARS-CoV-2 can also elicit an exaggerated host immune response, frequently leading to a cytokine storm, which significantly contributes to multiorgan dysfunction. 1 Indeed, high levels of circulating cytokines, particularly interleukin (IL)-6, are commonly found in patients with COVID-19, also associating with in-hospital death. 1 Accumulating data point to an increased cardiovascular disease morbidity and mortality in these patients. 1In particular, growing evidence suggest that COVID-19 is burdened by a higher risk of arrhythmic events, with important implications for survival. 1Heart palpitations were reported as one of the most common initial symptom of the disease (7.3%). 1 In 138 hospitalized patients with COVID-19, arrhythmias represented the leading complication (19.6%) after acute distress respiratory syndrome, particularly in those admitted to intensive care unit where the prevalence rose to 44.4%. 1 Specifically, malignant ventricular arrhythmias (ie, ventricular tachycardia/fibrillation) were found in 5.9% of cases. 1 It is currently believed that myocardial damage might represent a main driver of enhanced arrhythmic risk in these patients. 1Cardiac myocyte injury, reflected by increased troponin levels, was demonstrated in many individuals, particularly in those with severe disease.Accordingly, higher incidence of ventricular tachycardia/fibrillation was reported in patients with elevated troponin-T levels. 1 Although the mechanisms of myocardial involvement are still under investigation, they probably include direct viral infection, hypoxia-induced apoptosis, and cytokine storm-related cell damage (Figure ). 1 However, the evidence presented that in intensive care unit patients, despite the high frequency of arrhythmias (≈50% of cases), only half showed acute cardiac injury (with median troponin-I levels falling in the normal range), which suggests that factors other than myocardial damage are also involved in enhancing the arrhythmic risk in COVID-19.In this regard, the potential role of pharmacological treatments in enhancing the susceptibility to QT-related life-threatening ventricular arrhythmias, particularly Torsades de Pointes (TdP), is increasingly recognized. 1 In fact, some off-label drugs used to counteract the virus invasion and replication may promote corrected QTinterval (QTc) prolongation.This is the case of chloroquine/hydroxychloroquine, antimalarial agents blocking infection by increasing the endosomal pH required for virus/cell fusion, and lopinavir/ritonavir, protease inhibitors interfering with the virus RNA replication.Notably, in both cases, the impact on ventricular repolarization is direct, via inhibition of the hERG-K + channel, and also indirect by increasing circulating levels of other concomitant QT-prolonging drugs. 1 In fact, chloroquine and hydroxychloroquine inhibit CYP2D6 (cytochrome P450 2D6), which metabolizes several antipsychotics, antidepressants, and antihistamines,
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Driggin, E., Madhavan, M. V., Bikdeli, B., Chuich, T., Laracy, J., Biondi-Zoccai, G., Brown, T. S., Der Nigoghossian, C., Zidar, D. A., Haythe, J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.031 · Cited by 2,017
Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis
Lazzerini, P. E., Capecchi, P. L., & Laghi-Pasini, F. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw208 · Cited by 299
Self-citationCardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies
Lazzerini, P. E., Laghi-Pasini, F., Boutjdir, M., & Capecchi, P. L. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-018-0098-z · Cited by 169
Self-citationSystemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes
Lazzerini, P. E., Pasini, F. L., Bertolozzi, I., Morozzi, G., Lorenzini, S., Simpatico, A., Selvi, E., Bacarelli, M. R., Finizola, F., Vanni, F., et al. (2017) · Heart · doi:10.1136/heartjnl-2016-311079 · Cited by 119
Self-citationLazzerini, P. E., Acampa, M., Capecchi, P. L., Fineschi, I., Selvi, E., Moscadelli, V., Zimbone, S., Gentile, D., Galeazzi, M., & Pasini, F. L. (2014) · Arthritis Care & Research · doi:10.1002/acr.22455 · Cited by 100
Self-citation
Cited by
Seshadri, D. R., Davies, E. V., Harlow, E. R., Hsu, J. J., Knighton, S. C., Walker, T. A., Voos, J. E., & Drummond, C. K. (2020) · Frontiers in Digital Health · doi:10.3389/fdgth.2020.00008 · Cited by 298
He, L., Mäe, M. A., Muhl, L., Sun, Y., Pietilä, R., Nahar, K., Liébanas, E. V., Fagerlund, M. J., Oldner, A., Liu, J., et al. (2020) · doi:10.1101/2020.05.11.088500 · Cited by 116
Lazzerini, P. E., Acampa, M., Laghi-Pasini, F., Bertolozzi, I., Finizola, F., Vanni, F., Natale, M., Bisogno, S., Cevenini, G., Cartocci, A., et al. (2020) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.120.008627 · Cited by 74
Self-citationRubin, G. A., Desai, A. D., Chai, Z., Wang, A., Chen, Q., Wang, A. S., Kemal, C., Baksh, H., Biviano, A., Dizon, J. M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.6842 · Cited by 54
Metadata
- Authors
- Lazzerini, P. E., Boutjdir, M., & Capecchi, P. L.
- Venue
- Circulation
- Published
- 2020-07-07
- Volume
- 142
- Issue
- 1
- Pages
- 7-9
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W3015549620
- Cited by
- 254
- References
- 5
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COVID-19, Arrhythmic Risk, and Inflammation: Mind the Gap! https://app.cochat.ai/papers/10.1161/circulationaha.120.047293
- The paper
- Lazzerini, P. E., Boutjdir, M., & Capecchi, P. L. (2020). COVID-19, Arrhythmic Risk, and Inflammation: Mind the Gap! Circulation. https://doi.org/10.1161/circulationaha.120.047293
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.